Invetech and AiCella Collaborate to Enhance Cell Therapy with AI

Invetech and AiCella have announced a strategic collaboration to integrate AI into cell therapy production, aiming to optimize processes and improve patient outcomes.

Invetech and AiCella have announced a strategic collaboration to advance cell therapy innovation, as stated in a press release. This partnership aims to integrate AiCella's AI platform with Invetech's automation technology to enhance the development and manufacturing of cell therapies.

The collaboration focuses on embedding AiCella's predictive AI models into the cell therapy production process. This integration is expected to help therapy developers identify critical process parameters earlier, reduce manufacturing variability, and accelerate the path to scalable, patient-ready therapies.

Both companies plan to showcase their joint capabilities at upcoming industry events, including the Meeting on the Mesa in October 2025.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish like Life AI Weekly.

Also, consider following us on social media:

Healthcare & Life Sciences AI
AI Brief (X)

More from: Healthcare & Life Sciences

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more

You May Also Like